A line graph viewed on a computer monitor

NPS takes pride in providing state-of-the-art decision support products for clients to benchmark.

It is critical to be able to analyze the data our system captures in order to evaluate the effectiveness and efficiency of plan benefits. Using targeted database fields, we display the plan’s prescription costs in a readable and precise series of reports - the “Snapshot Report”. This information is presented in an easy-to-understand manner that is instantly applicable to future cost modeling as well as projecting the impact of potential changes to the design of the plan. The NPS Snapshot Report has become a valuable tool for our plans and their consultants as they navigate the pharmaceutical benefits maze!

We recognize that this data is powerful and valuable - and, at nps, data is protected.
It is not for sale.

The Snapshot Report Includes:

  • Plan Design Performance
    Information such as total number of claims, aggregate savings, savings per claim, co-pay and plan contribution amounts, and prescription averages are included in this report to help determine how a current plan is performing.
  • Brand and Generic Claims Summary
     This summary represents pharmacy claim types with color coding: single source brands (red), brands with generic (yellow), and generics (green). This information allows plans to accurately predict the member contributions in the red, yellow, and green claim zones when balancing the needs with the funds available for prescription drugs. Clients utilize this report to model their plans to accurately reflect cost shifts, cost share, and plan impact zones. This information may also be used to help equip plans with features designed to grow generic utilization faster, thus lowering claims dollar trend experiences. As a result, clients may continue offering their rich benefits while maintaining a competitive edge in their market place.
  • Utilization of Top Twenty-Five Drugs
    This report is designed to show where the dollars are spent in various drug categories. Although the drugs may have a multitude of off-label uses and clinical indications, we have translated the primary use of the drug category into layman’s terminology that facilitates strategic information about the plan. Diseases which are identified allow for the implementation of correct programs needed to help plan members with knowledge, awareness, and compliance to a drug therapy.
  • Top Twenty-Five Pharmacies by Prescription Counts
    Plans may review the top twenty-five pharmacy providers used by their members with this report and easily see the network delivery of discounts on products. Clients also see the level of substitution with the generic counterparts at these locations. Our plans understand the nature and necessity of providing appropriate funding to these providers and want them to share in the success of plan savings.
  • Top Twenty-Five Prescriber Utilization Summary
     Understanding what physicians are using in their current practice reflects the perception these healthcare officials have regarding the best therapies available in the market to date. These best therapies are available in both the generic program and the single source brand program.
  • Census Track and Utilization Based on Age and Gender
     The census audit may be used to verify the total head count for the plan. Due to fact that the American culture has shifted to dual income families, the opportunity for coordination of benefits becomes greater and plans need to provide funding for their claims only.
  • Mail Order Statistics
     Plan sponsors have the ability to review this key component of their program offering here. Formulary compliance, brand to generic substitution, member co-payment contribution, day supply, unit cost are all profiled in real time for plan sponsors to review and assess for value and savings for members as well as plan.
  • Top Ten Drug Classes
     This report helps align plan investment to the needs of the members. Additionally, drug recalls and formulary changes that may cause member disruptions become apparent. The report helps quickly determine how many members are using a particular drug and what will be the ultimate impact to the plan.
  • Preferred Drug List Utilization
     Use this report when considering formulary alignments. Plans may be surprised that their best solutions may be simply staying with a two-tier model (brand - generic). Alignment of a formulary should show a consistent and gradual claim cost escalation: 1st tier - $20, 2nd tier - $100, 3rd tier - $140; so if you chose to use a formulary co-pay system, the plan net cost should be aligned to the experience at point of sale and verified by these details.